And yet there is a good reason why the pharmaceutical industry can and should play a major role in financing something like a common “Innovation Fund” to provide financing for early-stage research into solving the problem of antimicrobial resistance. And that reason is one that I became familiar with during my years at Goldman Sachs: enlightened self-interest.